{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:23:55Z","timestamp":1771050235580,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01-AI061142"],"award-info":[{"award-number":["U01-AI061142"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272200800039C"],"award-info":[{"award-number":["HHSN272200800039C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.vaccine.2016.05.071","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T20:19:08Z","timestamp":1467058748000},"page":"3780-3786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax\u2122 delta inulin adjuvant"],"prefix":"10.1016","volume":"34","author":[{"given":"David L.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitar","family":"Sajkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Honda-Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel H.","family":"Wilks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malet","family":"Aban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian G.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-5245","authenticated-orcid":false,"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2016.05.071_b0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.vaccine.2005.04.018","article-title":"The impact of influenza on the health and health care utilisation of elderly people","volume":"23","author":"Fleming","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.071_b0010","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/glycob\/cwq201","article-title":"Delta inulin: a novel, immunologically active, stable packing structure comprising beta-D-[2\u21921] poly(fructo-furanosyl) alpha-d-glucose polymers","volume":"21","author":"Cooper","year":"2011","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2016.05.071_b0015","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/glycob\/cwt053","article-title":"The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions","volume":"23","author":"Cooper","year":"2013","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2016.05.071_b0020","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.carbpol.2013.12.066","article-title":"Inulin isoforms differ by repeated additions of one crystal unit cell","volume":"103","author":"Cooper","year":"2014","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.vaccine.2016.05.071_b0025","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1128\/JVI.03144-12","article-title":"JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8+ T cells and pre-exposure neutralizing antibody","volume":"87","author":"Larena","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.05.071_b0030","doi-asserted-by":"crossref","first-page":"10324","DOI":"10.1128\/JVI.00480-13","article-title":"An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody","volume":"87","author":"Petrovsky","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.05.071_b0035","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1099\/vir.0.023242-0","article-title":"Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations","volume":"92","author":"Cristillo","year":"2011","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.05.071_b0040","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.vaccine.2012.12.077","article-title":"A novel hepatitis B vaccine containing Advax, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing","volume":"31","author":"Saade","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.071_b0045","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.05.071_b0050","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.vaccine.2015.01.062","article-title":"A gold glyco-nanoparticle carrying a listeriolysin O peptide and formulated with Advax delta inulin adjuvant induces robust T-cell protection against listeria infection","volume":"33","author":"Rodriguez-Del Rio","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.071_b0055","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1128\/CVI.00019-14","article-title":"Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant","volume":"21","author":"Feinen","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.05.071_b0060","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.1016\/j.vaccine.2011.06.078","article-title":"Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets","volume":"29","author":"Layton","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.071_b0065","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1016\/j.vaccine.2014.06.057","article-title":"A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection","volume":"32","author":"Honda-Okubo","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.071_b0070","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1016\/j.vaccine.2015.07.051","article-title":"Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection","volume":"38","author":"Honda-Okubo","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.071_b0075","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1016\/j.vaccine.2012.06.009","article-title":"Randomized clinical trial of immunogenicity and safety of a recombinant H1N1\/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant","volume":"30","author":"Gordon","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.071_b0080","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1016\/j.vaccine.2014.09.034","article-title":"Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study","volume":"32","author":"Gordon","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.071_b0085","doi-asserted-by":"crossref","first-page":"P158","DOI":"10.1186\/1939-4551-6-S1-P158","article-title":"Immunotherapy \u2013 2076. A controlled study of delta inulin-adjuvanted honey bee venom immunotherapy","volume":"6","author":"Heddle","year":"2013","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.vaccine.2016.05.071_b0090","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1016\/j.vaccine.2012.06.021","article-title":"Advax, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses","volume":"30","author":"Honda-Okubo","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.071_b0095","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1256427","article-title":"Antibody landscapes after influenza virus infection or vaccination","volume":"346","author":"Fonville","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.05.071_b0100","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.4049\/jimmunol.179.7.4711","article-title":"Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination","volume":"179","author":"Koyama","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.05.071_b0105","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1016\/S0264-410X(99)00138-3","article-title":"Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly","volume":"17","author":"De Donato","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.071_b0110","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1016\/S0264-410X(03)00456-0","article-title":"Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults","volume":"21","author":"Frey","year":"2003","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2016.05.071_b0115","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3109\/00365548.2011.580777","article-title":"Explorations of clinical trials and pharmacovigilance databases of MF59\u00ae-adjuvanted influenza vaccines for associated cases of narcolepsy","volume":"43","author":"Tsai","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.05.071_b0120","doi-asserted-by":"crossref","first-page":"e33536","DOI":"10.1371\/journal.pone.0033536","article-title":"AS03 Adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland","volume":"7","author":"Nohynek","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.05.071_b0125","first-page":"522","article-title":"Inulin clearance as a screening test for kidney function","volume":"55","author":"Price","year":"1974","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.vaccine.2016.05.071_b0130","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.071_b0135","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1016\/j.vaccine.2011.06.010","article-title":"Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone(R)) administered by intradermal and intramuscular route in healthy adults","volume":"29","author":"Frenck","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.05.071_b0140","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.vaccine.2014.11.054","article-title":"Virus-specific T cells as correlate of (cross-)protective immunity against influenza","volume":"33","author":"Altenburg","year":"2015","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2016.05.071_b0145","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16303978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16303978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T04:44:21Z","timestamp":1568090661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16303978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":29,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0264410X16303978"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.05.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax\u2122 delta inulin adjuvant","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.05.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}